User menu

Ketolides : pharmacological profile and rational positioning in the treatment of respiratory tract infections

Bibliographic reference Van Bambeke, Françoise ; Harms, Joerg M ; Van Laethem, Yves ; Tulkens, Paul M.. Ketolides : pharmacological profile and rational positioning in the treatment of respiratory tract infections. In: Expert Opinion on Pharmacotherapy, Vol. 9, no. 2, p. 267-283 (2008)
Permanent URL
  1. Allen, Antimicrob Agents Chemother, 11, 669 (1977)
  2. Douthwaite S., Champney W. S., Structures of ketolides and macrolides determine their mode of interaction with the ribosomal target site, 10.1093/jac/48.suppl_2.1
  3. Wilson Daniel N., Harms Jörg M., Nierhaus Knud H., Schlünzen Frank, Fucini Paola, Species-specific antibiotic-ribosome interactions: implications for drug development, 10.1515/bc.2005.141
  4. Nilius A, Ketolides: the future of the macrolides?, 10.1016/s1471-4892(02)00198-4
  5. Canton R., Telithromycin activity is reduced by efflux in Streptococcus pyogenes, 10.1093/jac/dki033
  6. Ma Zhenkun, Nemoto Peter, Discovery and Development of Ketolides as a New Generation of Macrolide Antimicrobial Agents, 10.2174/1568012023355027
  7. Bryskier André, New research in macrolides and ketolides since 1997, 10.1517/13543784.8.8.1171
  8. Bryskier A., Ketolides—telithromycin, an example of a new class of antibacterial agents, 10.1046/j.1469-0691.2000.00185.x
  9. Agouridas, Antimicrob Agents Chemother, 41, 2149 (1997)
  10. Heggelund Audun, Undheim Kjell, Preparation of cyclic 2′,3′-carbamate derivatives of erythromycin macrolide antibiotics, 10.1016/j.bmc.2007.02.028
  11. Denis Alexis, Agouridas Constantin, Auger Jean-Michel, Benedetti Yannick, Bonnefoy Alain, Bretin François, Chantot Jean-François, Dussarat Arlette, Fromentin Claude, Gouin D'Ambrières Solange, Lachaud Sylvette, Laurin Patrick, Le Martret Odile, Loyau Véronique, Tessot Nicole, Pejac Jean-Marie, Perron Sébastien, Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens, 10.1016/s0960-894x(99)00534-x
  12. Zhu Bin, Marinelli Brett A., Abbanat Darren, Foleno Barbara D., Henninger Todd C., Bush Karen, Macielag Mark J., Synthesis and antibacterial activity of 3-O-acyl-6-O-carbamoyl erythromycin A derivatives, 10.1016/j.bmcl.2005.10.074
  13. Zhu Bin, Marinelli Brett A., Abbanat Darren, Foleno Barbara D., Bush Karen, Macielag Mark J., Synthesis and antibacterial activity of 3-keto-6-O-carbamoyl-11,12-cyclic thiocarbamate erythromycin A derivatives, 10.1016/j.bmcl.2007.04.104
  14. Tennakoon Manomi A., Henninger Todd C., Abbanat Darren, Foleno Barbara D., Hilliard Jamese J., Bush Karen, Macielag Mark J., Synthesis and antibacterial activity of C6-carbazate ketolides, 10.1016/j.bmcl.2006.09.036
  15. Grant Eugene B., Guiadeen Deodialsingh, Abbanat Darren, Foleno Barbara D., Bush Karen, Macielag Mark J., Synthesis and antibacterial activity of 6-O-heteroarylcarbamoyl-11,12-lactoketolides, 10.1016/j.bmcl.2005.12.097
  16. Agouridas Constantin, Denis Alexis, Auger Jean-Michel, Benedetti Yannick, Bonnefoy Alain, Bretin François, Chantot Jean-François, Dussarat Arlette, Fromentin Claude, D'Ambrières Solange Gouin, Lachaud Sylvette, Laurin Patrick, Le Martret Odile, Loyau Véronique, Tessot Nicole, Synthesis and Antibacterial Activity of Ketolides (6-O-Methyl-3-oxoerythromycin Derivatives):  A New Class of Antibacterials Highly Potent Against Macrolide-Resistant and -Susceptible Respiratory Pathogens†, 10.1021/jm980240d
  17. Henninger Todd C., Xu Xiaodong, Abbanat Darren, Baum Ellen Z., Foleno Barbara D., Hilliard Jamese J., Bush Karen, Hlasta Dennis J., Macielag Mark J., Synthesis and antibacterial activity of C-6 carbamate ketolides, a novel series of orally active ketolide antibiotics, 10.1016/j.bmcl.2004.06.045
  18. Ma Zhenkun, Clark Richard F., Brazzale Antony, Wang Sanyi, Rupp Michael J., Li Leping, Griesgraber George, Zhang Suoming, Yong Hong, Phan Ly Tam, Nemoto Peter A., Chu Daniel T. W., Plattner Jacob J., Zhang Xiaolin, Zhong Ping, Cao Zhensheng, Nilius Angela M., Shortridge Virginia D., Flamm Robert, Mitten Michael, Meulbroek Jon, Ewing Patty, Alder Jeff, Or Yat Sun, Novel Erythromycin Derivatives with Aryl Groups Tethered to the C-6 Position Are Potent Protein Synthesis Inhibitors and Active against Multidrug-Resistant Respiratory Pathogens, 10.1021/jm0102349
  19. &NA;, Cethromycin : A-195773, A-195773-0, A-1957730, Abbott-195773, ABT 773, 10.2165/00126839-200708020-00004
  20. Revill P., Bolos J., Serradell N., EDP-420, 10.1358/dof.2006.031.06.997162
  21. Kirst, Antimicrob Agents Chemother, 33, 1413 (1989)
  22. Nagai K., Davies T. A., Ednie L. M., Bryskier A., Palavecino E., Jacobs M. R., Appelbaum P. C., Activities of a New Fluoroketolide, HMR 3787, and Its (Des)-Fluor Derivative RU 64399 Compared to Those of Telithromycin, Erythromycin A, Azithromycin, Clarithromycin, and Clindamycin against Macrolide-Susceptible or -Resistant Streptococcus pneumoniae and S. pyogenes, 10.1128/aac.45.11.3242-3245.2001
  23. Abbanat D., Webb G., Foleno B., Li Y., Macielag M., Montenegro D., Wira E., Bush K., In Vitro Activities of Novel 2-Fluoro-Naphthyridine-Containing Ketolides, 10.1128/aac.49.1.309-315.2005
  24. Guitton M., In vitro and in vivo efficacy of a novel fluoro-ketolide HMR 3562 against enterococci, 10.1093/jac/48.1.131
  25. Nomura Takashi, Yasukata Tatsuro, Narukawa Yukitoshi, Uotani Kouichi, 9-Oxime-3-ketolides: Modification at the C-11,12-diol moiety and antibacterial activities against key respiratory pathogens, 10.1016/j.bmc.2005.06.003
  26. Nomura Takashi, Iwaki Tsutomu, Narukawa Yukitoshi, Uotani Koichi, Hori Toshihiko, Miwa Hideaki, A new type of ketolide bearing an N-aryl-alkyl acetamide moiety at the C-9 iminoether: Synthesis and structure–activity relationships (2), 10.1016/j.bmc.2006.01.036
  27. Nomura Takashi, Iwaki Tsutomu, Yasukata Tatsuro, Nishi Koichi, Narukawa Yukitoshi, Uotani Koichi, Hori Toshihiko, Miwa Hideaki, A new type of ketolides bearing an N-aryl-alkyl acetamide moiety at the C-9 iminoether synthesis and structure–activity relationships, 10.1016/j.bmc.2005.07.041
  28. Burger Matthew T., Lin Xiaodong, Chu Daniel T., Hiebert Christy, Rico Alice C., Seid Mehran, Carroll Georgia L., Barker Lynn, Huh Kay, Langhorne Mike, Shawar Ribhi, Kidney Jolene, Young Kelly, Anderson Scott, Desai Manoj C., Plattner Jacob J., Synthesis and Antibacterial Activity of Novel C12Vinyl Ketolides, 10.1021/jm051157a
  29. Burger Matthew T., Hiebert Christy, Seid Mehran, Chu Daniel T., Barker Lynn, Langhorne Mike, Shawar Ribhi, Kidney Jolene, Desai Manoj C., Plattner Jacob J., Synthesis and antibacterial activity of novel C12 ethyl ketolides, 10.1016/j.bmc.2006.04.032
  30. Ištuk Zorica Marušić, Mutak Stjepan, Kujundžić Nedjeljko, Kragol Goran, Novel 9a-carbamoyl- and 9a-thiocarbamoyl-3-decladinosyl-6-hydroxy and 6-methoxy derivatives of 15-membered macrolides, 10.1016/j.bmc.2007.04.021
  31. Ono, J Antibiot (Tokyo), 57, 518 (2004)
  32. Morosini M.-I., Streptococcus pyogenes isolates with characterized macrolide resistance mechanisms in Spain: in vitro activities of telithromycin and cethromycin, 10.1093/jac/dkg303
  33. Shortridge V. D., Zhong P., Cao Z., Beyer J. M., Almer L. S., Ramer N. C., Doktor S. Z., Flamm R. K., Comparison of In Vitro Activities of ABT-773 and Telithromycin against Macrolide-Susceptible and -Resistant Streptococci and Staphylococci, 10.1128/aac.46.3.783-786.2002
  34. Hammerschlag M. R., Roblin P. M., Bebear C. M., Activity of telithromycin, a new ketolide antibacterial, against atypical and intracellular respiratory tract pathogens, 10.1093/jac/48.suppl_2.25
  35. FELMINGHAM D, FARRELL D, In vitro activity of telithromycin against Gram-negative bacterial pathogens, 10.1016/j.jinf.2005.05.014
  36. Stout Janet E., Sens Kelly, Mietzner Sue, Obman Asia, Yu Victor L., Comparative activity of quinolones, macrolides and ketolides against Legionella species using in vitro broth dilution and intracellular susceptibility testing, 10.1016/j.ijantimicag.2004.08.019
  37. Edelstein P. H., Higa F., Edelstein M. A. C., In Vitro Activity of ABT-773 against Legionella pneumophila, Its Pharmacokinetics in Guinea Pigs, and Its Use to Treat Guinea Pigs with L. pneumophila Pneumonia, 10.1128/aac.45.10.2685-2690.2001
  38. Edelstein, Antimicrob Agents Chemother, 43, 90 (1999)
  39. Farrell D. J., Shackcloth J., Barbadora K. A., Green M. D., Streptococcus pyogenes Isolates with High-Level Macrolide Resistance and Reduced Susceptibility to Telithromycin Associated with 23S rRNA Mutations, 10.1128/aac.50.2.817-818.2006
  40. Farrell D. J., File T. M., Jenkins S. G., Prevalence and Antibacterial Susceptibility of mef(A)-Positive Macrolide-Resistant Streptococcus pneumoniae over 4 Years (2000 to 2004) of the PROTEKT US Study, 10.1128/jcm.01653-06
  41. Doern Gary V., Macrolide and Ketolide Resistance with Streptococcus pneumoniae, 10.1016/j.mcna.2006.07.010
  42. Douthwaite Stephen, Jalava Jari, Jakobsen Lene, Ketolide resistance inStreptococcus pyogenescorrelates with the degree of rRNA dimethylation by Erm : Ketolide resistance and dimethylation by Erm, 10.1111/j.1365-2958.2005.04863.x
  43. Farrell D. J., The PROTEKT global study (year 4) demonstrates a continued lack of resistance development to telithromycin in Streptococcus pneumoniae, 10.1093/jac/dki282
  44. Rantala M., Haanpera-Heikkinen M., Lindgren M., Seppala H., Huovinen P., Jalava J., , Streptococcus pneumoniae Isolates Resistant to Telithromycin, 10.1128/aac.50.5.1855-1858.2006
  45. Hsueh P.-R., Teng L.-J., Wu T.-L., Yang D., Huang W.-K., Shyr J.-M., Chuang Y.-C., Wan J.-H., Yan J.-J., Lu J.-J., Wu J.-J., Ko W.-C., Chang F.-Y., Yang Y.-C., Lau Y.-J., Liu Y.-C., Lee C.-M., Leu H.-S., Liu C.-Y., Luh K.-T., Telithromycin- and Fluoroquinolone-Resistant Streptococcus pneumoniae in Taiwan with High Prevalence of Resistance to Macrolides and  -Lactams: SMART Program 2001 Data, 10.1128/aac.47.7.2145-2151.2003
  46. Malhotra-Kumar, Emerg Infect Dis, 11, 939 (2005)
  47. Grivea I. N., Al-Lahham A., Katopodis G. D., Syrogiannopoulos G. A., Reinert R. R., Resistance to Erythromycin and Telithromycin in Streptococcus pyogenes Isolates Obtained between 1999 and 2002 from Greek Children with Tonsillopharyngitis: Phenotypic and Genotypic Analysis, 10.1128/aac.50.1.256-261.2006
  48. Wolter N., Smith A. M., Low D. E., Klugman K. P., High-Level Telithromycin Resistance in a Clinical Isolate of Streptococcus pneumoniae, 10.1128/aac.01153-06
  49. Al-Lahham A., Appelbaum P. C., van der Linden M., Reinert R. R., Telithromycin-Nonsusceptible Clinical Isolates of Streptococcus pneumoniae from Europe, 10.1128/aac.00057-06
  50. Hirakata, Jpn J Infect Dis, 60, 48 (2007)
  51. Hisanaga T., Mechanisms of resistance to telithromycin in Streptococcus pneumoniae, 10.1093/jac/dki249
  52. Berisio R., Corti N., Pfister P., Yonath A., Bottger E. C., 23S rRNA 2058A->G Alteration Mediates Ketolide Resistance in Combination with Deletion in L22, 10.1128/aac.00767-06
  53. Canu A., Malbruny B., Coquemont M., Davies T. A., Appelbaum P. C., Leclercq R., Diversity of Ribosomal Mutations Conferring Resistance to Macrolides, Clindamycin, Streptogramin, and Telithromycin in Streptococcus pneumoniae, 10.1128/aac.46.1.125-131.2002
  54. Walsh F., High-level telithromycin resistance in laboratory-generated mutants of Streptococcus pneumoniae, 10.1093/jac/dkg348
  55. Xiong Liqun, Shah Sunita, Mauvais Pascale, Mankin Alexander S., A ketolide resistance mutation in domain II of 23S rRNA reveals the proximity of hairpin 35 to the peptidyl transferase centre, 10.1046/j.1365-2958.1999.01203.x
  56. Reinert R. R., van der Linden M., Al-Lahham A., Molecular Characterization of the First Telithromycin-Resistant Streptococcus pneumoniae Isolate in Germany, 10.1128/aac.49.8.3520-3522.2005
  57. Bogdanovich T., Bozdogan B., Appelbaum P. C., Effect of Efflux on Telithromycin and Macrolide Susceptibility in Haemophilus influenzae, 10.1128/aac.50.3.893-898.2006
  58. Reynolds E. D., Resistance to telithromycin is conferred by msr(A), msrC and msr(D) in Staphylococcus aureus, 10.1093/jac/dki378
  59. Kerr I.D., Reynolds E.D., Cove J.H., ABC proteins and antibiotic drug resistance: is it all about transport?, 10.1042/bst0331000
  60. Chesneau Olivier, Tsvetkova Krassimira, Courvalin Patrice, Resistance phenotypes conferred by macrolide phosphotransferases : Resistance conferred by macrolide phosphotransferases, 10.1111/j.1574-6968.2007.00643.x
  61. Carryn Stéphane, Chanteux Hugues, Seral Cristina, Mingeot-Leclercq Marie-Paule, Van Bambeke Françoise, Tulkens Paul M, Intracellular pharmacodynamics of antibiotics, 10.1016/s0891-5520(03)00066-7
  62. Vazifeh D., Bryskier A., Labro M. T., Effect of Proinflammatory Cytokines on the Interplay between Roxithromycin, HMR 3647, or HMR 3004 and Human Polymorphonuclear Neutrophils, 10.1128/aac.44.3.511-521.2000
  63. Vazifeh, Antimicrob Agents Chemother, 42, 1944 (1998)
  64. Bosnar M., Kelneric Z., Munic V., Erakovic V., Parnham M. J., Cellular Uptake and Efflux of Azithromycin, Erythromycin, Clarithromycin, Telithromycin, and Cethromycin, 10.1128/aac.49.6.2372-2377.2005
  65. Labro M. T., Abdelghaffar H., Babin-Chevaye C., Interaction of the New Ketolide ABT-773 (Cethromycin) with Human Polymorphonuclear Neutrophils and the Phagocytic Cell Line PLB-985 In Vitro, 10.1128/aac.48.4.1096-1104.2004
  66. Seral C., Michot J.-M., Chanteux H., Mingeot-Leclercq M.-P., Tulkens P. M., Van Bambeke F., Influence of P-Glycoprotein Inhibitors on Accumulation of Macrolides in J774 Murine Macrophages, 10.1128/aac.47.3.1047-1051.2003
  67. Seral C., Influence of P-glycoprotein and MRP efflux pump inhibitors on the intracellular activity of azithromycin and ciprofloxacin in macrophages infected by Listeria monocytogenes or Staphylococcus aureus, 10.1093/jac/dkg223
  68. Yamaguchi S., Zhao Y. L., Nadai M., Yoshizumi H., Cen X., Torita S., Takagi K., Takagi K., Hasegawa T., Involvement of the Drug Transporters P Glycoprotein and Multidrug Resistance-Associated Protein Mrp2 in Telithromycin Transport, 10.1128/aac.50.1.80-87.2006
  69. Kuehnel T. S., Penetration of telithromycin into the nasal mucosa and ethmoid bone of patients undergoing rhinosurgery for chronic sinusitis, 10.1093/jac/dki034
  70. Tessier P. R., Mattoes H. M., Dandekar P. K., Nightingale C. H., Nicolau D. P., Pharmacodynamic Profile of Telithromycin against Macrolide- and Fluoroquinolone-Resistant Streptococcus pneumoniae in a Neutropenic Mouse Thigh Model, 10.1128/aac.49.1.188-194.2005
  71. Azoulay-Dupuis E., Mohler J., Bedos J. P., Barau C., Fantin B., Efficacy of Cethromycin, a New Ketolide, against Streptococcus pneumoniae Susceptible or Resistant to Erythromycin in a Murine Pneumonia Model, 10.1128/aac.00920-05
  72. Barcia-Macay M., Seral C., Mingeot-Leclercq M.-P., Tulkens P. M., Van Bambeke F., Pharmacodynamic Evaluation of the Intracellular Activities of Antibiotics against Staphylococcus aureus in a Model of THP-1 Macrophages, 10.1128/aac.50.3.841-851.2006
  73. Lodise Thomas P., Preston Sandra, Bhargava Vijay, Bryskier Andre, Nusrat Roomi, Chapel Sonny, Rangaraju Manichan, Drusano George L., Pharmacodynamics of an 800-mg dose of telithromycin in patients with community-acquired pneumonia caused by extracellular pathogens, 10.1016/j.diagmicrobio.2004.12.005
  74. Zhanel G. G., Johanson C., Laing N., Hisanaga T., Wierzbowski A., Hoban D. J., Pharmacodynamic Activity of Telithromycin at Simulated Clinically Achievable Free-Drug Concentrations in Serum and Epithelial Lining Fluid against Efflux (mefE)-Producing Macrolide- Resistant Streptococcus pneumoniae for Which Telithromycin MICs Vary, 10.1128/aac.49.5.1943-1948.2005
  75. Shi Jun, Pfister Marc, Jenkins Stephen G, Chapel Sunny, Barrett Jeffrey S, Port Ruedi E, Howard Dan, Pharmacodynamic Analysis of the Microbiological Efficacy of Telithromycin in Patients with Community-Acquired Pneumonia : , 10.2165/00003088-200544030-00007
  76. Shi Jun, Montay Guy, Bhargava Vijay O, Clinical Pharmacokinetics of Telithromycin, the First Ketolide Antibacterial : , 10.2165/00003088-200544090-00003
  77. Ciervo Carman A., Shi Jun, Pharmacokinetics of telithromycin: application to dosing in the treatment of community-acquired respiratory tract infections, 10.1185/030079905x65466
  78. Reed Matthew, Wall Geoffrey C, Shah Niyati P, Heun James M, Hicklin Gregory A, Verapamil Toxicity Resulting from a Probable Interaction with Telithromycin, 10.1345/aph.1e496
  79. Nenciu Laura M, Laberge Patrice, Thirion Daniel J. G, Telithromycin-Induced Digoxin Toxicity and Electrocardiographic Changes, 10.1592/phco.26.6.872
  80. Lonks J. R., Goldmann D. A., Telithromycin: A Ketolide Antibiotic for Treatment of Respiratory Tract Infections, 10.1086/430067
  81. Seithel A., Eberl S., Singer K., Auge D., Heinkele G., Wolf N. B., Dorje F., Fromm M. F., Konig J., The Influence of Macrolide Antibiotics on the Uptake of Organic Anions and Drugs Mediated by OATP1B1 and OATP1B3, 10.1124/dmd.106.014407
  82. Niederman Michael S., Principles of appropriate antibiotic use, 10.1016/s0924-8579(05)80324-3
  83. Das Biswadeep, Sarkar Chayna, Majumder Abhijeet Guha, Medication use for pediatric upper respiratory tract infections, 10.1111/j.1472-8206.2006.00414.x
  84. MacDougall, Emerg Infect Dis, 11, 380 (2005)
  85. Poole Michael D, A focus on acute sinusitis in adults: changes in disease management, 10.1016/s0002-9343(98)00352-0
  86. Cooper, Ann Intern Med, 134, 509 (2001)
  87. Rennard S., Decramer M., Calverley P.M.A., Pride N.B., Soriano J.B., Vermeire P.A., Vestbo J., Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey, 10.1183/09031936.02.03242002
  88. Huchon G.J., Vergnenegre A., Neukirch F., Brami G., Roche N., Preux P-M., Chronic bronchitis among French adults: high prevalence and underdiagnosis, 10.1183/09031936.02.00042002
  89. Niederman Michael S., McCombs Jeffrey S., Unger Alan N., Kumar Amit, Popovian Robert, The cost of treating community-acquired pneumonia, 10.1016/s0149-2918(98)80144-6
  90. Hoban Daryl J, Zhanel George G, Clinical implications of macrolide resistance in community-acquired respiratory tract infections, 10.1586/14787210.4.6.973
  91. Van, Drugs, 67, 2355 (2007)
  92. Norrby S.R., Quinn J., Rangaraju M., Leroy B., Evaluation of 5-day therapy with telithromycin, a novel ketolide antibacterial, for the treatment of tonsillopharyngitis, 10.1111/j.1469-0691.2004.00908.x
  93. S. Ragnar Norrby, Willem J. Rabie,, Efficacy of Short-course Therapy with the Ketolide Telithromycin Compared with 10 Days of Penicillin V for the Treatment of Pharyngitis/Tonsillitis, 10.1080/00365540110077443
  94. Quinn James, Ruoff Gary E., Ziter Paul S., Efficacy and tolerability of 5-day, once-daily telithromycin compared with 10-day, twice-daily clarithromycin for the treatment of group A beta-hemolytic streptococcal tonsillitis/pharyngitis: A multicenter, randomized, double-blind, parallel-group study, 10.1016/s0149-2918(03)80087-5
  95. Brook Itzhak, Hausfeld Jeffrey N., Effect of Telithromycin and Azithromycin on Nasopharyngeal Bacterial Flora in Patients With Acute Maxillary Sinusitis, 10.1001/archotol.132.4.442
  96. Carbon, Infection, 31, 308 (2003)
  97. Buchanan, Am J Rhinol, 17, 369 (2003)
  98. Luterman, Ear Nose Throat J, 82, 576 (2003)
  99. Roos K., Brunswig-Pitschner C., Kostrica R., Pietola M., Leroy B., Rangaraju M., Boutalbi Y., Efficacy and Tolerability of Once-Daily Therapy with Telithromycin for 5 or 10 Days for the Treatment of Acute Maxillary Sinusitis, 10.1159/000057670
  100. ROOS K, TELLIER G, BAZ M, LEROY B, RANGARAJU M, Clinical and bacteriological efficacy of 5-day telithromycin in acute maxillary sinusitis: a pooled analysis, 10.1016/j.jinf.2004.05.014
  101. Tran, Proc (Bayl Univ Med Cent), 17, 475 (2004)
  102. Ferguson Berrylin J., Guzzetta Richard V., Spector Sheldon L., Hadley James A., Efficacy and Safety of Oral Telithromycin Once Daily for 5 Days Versus Moxifloxacin Once Daily for 10 Days in the Treatment of Acute Bacterial Rhinosinusitis, 10.1016/j.otohns.2004.05.010
  103. Marple Bradley F., Brunton Stephen, Ferguson Berrylin J., Acute bacterial rhinosinusitis: A review of U.S. treatment guidelines, 10.1016/j.otohns.2005.12.021
  104. Anon J. B., Current Management of Acute Bacterial Rhinosinusitis and the Role of Moxifloxacin, 10.1086/428057
  105. AUBIER M, ALDONS P.M, LEAK A, MCKEITH D.D, LEROY B, RANGARAJU M, BIENFAIT-BEUZON C, Telithromycin is as effective as amoxicillin/clavulanate in acute exacerbations of chronic bronchitis, 10.1053/rmed.2002.1382
  106. Zervos, J Int Med Res, 31, 157 (2003)
  107. Fogarty Charles, de Wet Ronelle, Mandell Lionel, Chang Joanne, Rangaraju Manickam, Nusrat Roomi, Five-Day Telithromycin Once Daily Is as Effective as 10-Day Clarithromycin Twice Daily for the Treatment of Acute Exacerbations of Chronic Bronchitis and Is Associated With Reduced Health-Care Resource Utilization, 10.1378/chest.128.4.1980
  108. Johnston Sebastian L., Blasi Francesco, Black Peter N., Martin Richard J., Farrell David J., Nieman Richard B., The Effect of Telithromycin in Acute Exacerbations of Asthma, 10.1056/nejmoa044080
  109. Amsden G. W., Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?, 10.1093/jac/dkh519
  110. Ferrara G., Losi M., Franco F., Corbetta L., Fabbri L.M., Richeldi L., Macrolides in the treatment of asthma and cystic fibrosis, 10.1016/j.rmed.2004.09.014
  111. Mathers Dunbar Lala, Hassman Joseph, Tellier Guy, Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults, 10.1016/s0149-2918(04)90005-7
  112. Hagberg L., Torres A., van Rensburg D., Leroy B., Rangaraju M., Ruuth E., Efficacy and Tolerability of Once-Daily Telithromycin Compared with High-Dose Amoxicillin for Treatment of Community-Acquired Pneumonia, 10.1007/s15010-002-2096-z
  113. Pullman, Int J Clin Pract, 57, 377 (2003)
  114. Tellier G., Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia, 10.1093/jac/dkh356
  115. van, Chemotherapy, 51, 186 (2005)
  116. Fogarty Charles M, Patel Tushar C, Dunbar Lala M, Leroy Bruno P, Efficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter study, 10.1186/1471-2334-5-43
  117. Carbon C., Moola S., Velancsics I., Leroy B., Rangaraju M., Decosta P., Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia, 10.1046/j.1469-0691.2003.00678.x
  118. Carbon C., van Rensburg D., Hagberg L., Fogarty C., Tellier G., Rangaraju M., Nusrat R., Clinical and bacteriologic efficacy of telithromycin in patients with bacteremic community-acquired pneumonia, 10.1016/j.rmed.2005.11.007
  119. Mandell L. A., Wunderink R. G., Anzueto A., Bartlett J. G., Campbell G. D., Dean N. C., Dowell S. F., File T. M., Musher D. M., Niederman M. S., Torres A., Whitney C. G., Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults, 10.1086/511159
  120. Woodhead M., Guidelines for the management of adult lower respiratory tract infections, 10.1183/09031936.05.00055705
  121. Bearden David T., Neuhauser Melinda M., Garey Kevin W., Telithromycin: An Oral Ketolide for Respiratory Infections, 10.1592/phco.21.15.1204.33902
  122. Clay Kimberly D., Brief Communication: Severe Hepatotoxicity of Telithromycin: Three Case Reports and Literature Review, 10.7326/0003-4819-144-6-200503210-00121
  123. Soreth Janice, Cox Edward, Kweder Sandra, Jenkins John, Galson Steven, Ketek — The FDA Perspective, 10.1056/nejmc076135
  124. Ross David B., The FDA and the Case of Ketek, 10.1056/nejmp078032
  125. Perrot X., Bernard N., Vial C., Antoine J. C., Laurent H., Vial T., Confavreux C., Vukusic S., Myasthenia gravis exacerbation or unmasking associated with telithromycin treatment, 10.1212/01.wnl.0000247741.72466.8c
  126. Gupta Akshay, Lawrence Andrew T., Krishnan Kousik, Kavinsky Clifford J., Trohman Richard G., Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes, 10.1016/j.ahj.2007.01.040
  127. Goossens, Lancet, 365, 579 (2005)
  128. Coenen Samuel, Ferech Matus, Malhotra-Kumar Surbhi, Hendrickx Erik, Suetens Carl, Goossens Herman, European Surveillance of Antimicrobial Consumption (ESAC): outpatient macrolide, lincosamide and streptogramin (MLS) use in Europe, 10.1093/jac/dkl184
  129. Goossens H., Ferech M., Coenen S., Stephens P., , Comparison of Outpatient Systemic Antibacterial Use in 2004 in the United States and 27 European Countries, 10.1086/512810
  130. Van Bambeke F., Michot J.-M., Van Eldere J., Tulkens P.M., Quinolones in 2005: an update, 10.1111/j.1469-0691.2005.01131.x
  131. Jorgensen J. H., Crawford S. A., McElmeel M. L., Whitney C. G., Activities of Cethromycin and Telithromycin against Recent North American Isolates of Streptococcus pneumoniae, 10.1128/aac.48.2.605-607.2004
  132. Schmitz F.-J., In vitro activities of the ketolides ABT-773 and telithromycin and of three macrolides against genetically characterized isolates of Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and Moraxella catarrhalis, 10.1093/jac/dkf085
  133. Giovanetti E., In vitro activity of ketolides telithromycin and HMR 3004 against Italian isolates of Streptococcus pyogenes and Streptococcus pneumoniae with different erythromycin susceptibility, 10.1093/jac/46.6.905
  134. Waites K. B., Crabb D. M., Duffy L. B., In Vitro Activities of ABT-773 and Other Antimicrobials against Human Mycoplasmas, 10.1128/aac.47.1.39-42.2003
  135. Khair O. A., Lung concentrations of telithromycin after oral dosing, 10.1093/jac/47.6.837
  136. Muller-Serieys C., Soler P., Cantalloube C., Lemaitre F., Gia H. P., Brunner F., Andremont A., Bronchopulmonary Disposition of the Ketolide Telithromycin (HMR 3647), 10.1128/aac.45.11.3104-3108.2001
  137. Conte J. E., Golden J. A., Kipps J., Zurlinden E., Steady-State Plasma and Intrapulmonary Pharmacokinetics and Pharmacodynamics of Cethromycin, 10.1128/aac.48.9.3508-3515.2004
  138. KAJOSAARI L, NIEMI M, BACKMAN J, NEUVONEN P, Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide, 10.1016/j.clpt.2005.11.002
  139. Berisio R., Harms J., Schluenzen F., Zarivach R., Hansen H. A. S., Fucini P., Yonath A., Structural Insight into the Antibiotic Action of Telithromycin against Resistant Mutants, 10.1128/jb.185.14.4276-4279.2003
  140. Tu Daqi, Blaha Gregor, Moore Peter B., Steitz Thomas A., Structures of MLSBK Antibiotics Bound to Mutated Large Ribosomal Subunits Provide a Structural Explanation for Resistance, 10.1016/j.cell.2005.02.005
  141. Cannone Jamie J, Subramanian Sankar, Schnare Murray N, Collett James R, D'Souza Lisa M, Du Yushi, Feng Brian, Lin Nan, Madabusi Lakshmi V, Müller Kirsten M, Pande Nupur, Shang Zhidi, Yu Nan, Gutell Robin R, 10.1186/1471-2105-3-2
  142. Douthwaite, Clin Microbiol Infect, 7, 11 (2001)